Esketamine performs well when it is administered intravenously. At a dosage of 0.4 mg/kg — average of 31.2mg per participant — it provided a 13.4-point reduction of symptoms according to the 60-point MADRS after 3 days. The result was significant at (p ≥ 0.009). Placebo only reached a reduction of 3-points.
There is currently only one trial of Arketamine in progress however an open label pilot study saw a 20.3-point reduction of symptoms on the MADRS after 3 days. There are many confounders; the dosage was higher at 0.5mg/kg — average of 36.7mg per participant — as it was only a pilot study there was no placebo group and there were only 7 participants, all of which were female. However result was significant at (p ≥ 0.001).
Arketamine is currently entering Phase II clinical trials for treatment-resistant depression. Market will end after Phase III trial data is released and compared with Esketamine efficacy.
Esketamine Trials:
Arketamine Trials:
Apr 17, 6:25pm: Which enantiomer of Ketamine will provide a greater anti-depressant effect? → Will Arketamine promote a greater anti-depressant effect than Esketamine?
1,000
3.00